Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H

HHKEX:3378
26.96
HKD
+0.66
(+2.51%)
3.85BMarket Cap
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
-0.56
-0.85
-1.11
- -
Free Cash Flow per Basic Share
-0.42
-0.82
-0.88
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
1.97
1.22
5.12
4.7
Tangible Book Value per Share
1.96
1.22
5.12
4.7
Basic Weighted Avg Shares
136
136
118
136
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
1
5
6
- -
Net Income, GAAP
-76
-116
-131
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
Working Capital
236
45
597
578
LT Debt
12
9
22
70
Total Equity
320
217
748
686
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
-53.33
-30.33
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Jun'26
ST Debt
34
3
LT Borrowings
17
67
LT Finance Leases
5
4
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
136
135
Market Capitalization
1,956
3,329

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Jun'26
Total Current Assets
692
611
Cash, Cash Equivalents & STI
652
544
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
95
33
Payables & Accruals
- -
- -
ST Debt
34
3
Deferred Revenue
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
245.15%
Free Cash Flow
- -
- -
-6.1%
Net Income, GAAP
- -
- -
13.1%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.85
2025
- -
- -
-1.11
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Qi Xiang Li
Full Time Employees
64
Sector
Health technology
Industry
Biotechnology
Address
Building A8, Phase II Wuhan China 361013
IPO Date
Dec 23, 2025
Business
Xiamen International Port Co., Ltd. is a leading port operator in China, principally engaged in container loading and unloading and storage; bulk and general cargo loading and unloading and storage; ancillary value-added port services including port-related logistics, shipping agency, tugboat berthing and unberthing, and tallying; manufacturing and selling of building materials; and trading business of merchandise. The company operates through key terminals such as Haitian Terminal, XICT, Hairun Terminal, XHICT, and Dongdu Terminal in the Dongdu and Haicang port areas of Xiamen City, with additional operations in Qingzhou operating area in Fuzhou, Quanzhou port, and self-owned berths in Sanbaimen new port area of Chaozhou City, Guangdong Province; it also provides agency services for international air transportation through subsidiaries and focuses on customers in international and domestic trade across the People's Republic of China. Founded in 1998 and headquartered at 127 Dongdu Road, Xiamen, Fujian Province, the company, which listed its H-shares on the Hong Kong Stock Exchange in 2005, employs 7,212 staff and maintains a parent-subsidiary relationship with Xiamen Port Development Co., Ltd., its controlling entity. In a significant recent development, Xiamen Port Development Co., Ltd., a subsidiary, agreed in August 2025 to acquire a 70% stake in Xiamen Container Terminal Group Co., Ltd. from Xiamen International Port Co., Ltd. for CNY 7.6 billion in a mixed cash and share transaction subject to regulatory approvals, aimed at consolidating container terminal operations.